TRDA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TRDA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Entrada Therapeutics's Revenue for the three months ended in Mar. 2024 was $59.1 Mil. Entrada Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $490.0 Mil. Therefore, Entrada Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.12.
Asset Turnover is linked to ROE % through Du Pont Formula. Entrada Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was 36.73%. It is also linked to ROA % through Du Pont Formula. Entrada Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was 19.18%.
The historical data trend for Entrada Therapeutics's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Asset Turnover | - | - | - | - | 0.36 |
Entrada Therapeutics Quarterly Data | |||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Asset Turnover | Get a 7-Day Free Trial | 0.07 | 0.04 | 0.09 | 0.09 | 0.12 |
For the Biotechnology subindustry, Entrada Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Entrada Therapeutics's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
Entrada Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2023 ) | / | ( (Total Assets (A: Dec. 2022 ) | + | Total Assets (A: Dec. 2023 )) | / count ) |
= | 129.013 | / | ( (252.056 | + | 469.192) | / 2 ) |
= | 129.013 | / | 360.624 | |||
= | 0.36 |
Entrada Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Mar. 2024 ) | / | ( (Total Assets (Q: Dec. 2023 ) | + | Total Assets (Q: Mar. 2024 )) | / count ) |
= | 59.12 | / | ( (469.192 | + | 510.844) | / 2 ) |
= | 59.12 | / | 490.018 | |||
= | 0.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Entrada Therapeutics (NAS:TRDA) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Entrada Therapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is
ROE %** | (Q: Mar. 2024 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 93.984 | / | 255.8635 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (93.984 / 236.48) | * | (236.48 / 490.018) | * | (490.018/ 255.8635) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 39.74 % | * | 0.4826 | * | 1.9152 |
= | ROA % | * | Equity Multiplier | ||
= | 19.18 % | * | 1.9152 | ||
= | 36.73 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Entrada Therapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is
ROA % | (Q: Mar. 2024 ) | ||
= | Net Income | / | Total Assets |
= | 93.984 | / | 490.018 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (93.984 / 236.48) | * | (236.48 / 490.018) |
= | Net Margin % | * | Asset Turnover |
= | 39.74 % | * | 0.4826 |
= | 19.18 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of Entrada Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Dipal Doshi | director, officer: President and CEO | C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Kory James Wentworth | officer: Chief Financial Officer | 6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210 |
Nathan J Dowden | officer: Chief Operating Officer | 6 TIDE STREET, BOSTON MA 02210 |
Nerissa Kreher | officer: Chief Medical Officer | C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139 |
Gina Chapman | director | C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403 |
Natarajan Sethuraman | officer: Chief Scientific Officer | 6 TIDE STREET, BOSTON MA 02210 |
Bernhardt G Zeiher | director | ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210 |
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Todd Foley | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Felix Baker | 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors (gp) Llc | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
John F Crowley | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Mpm Bioventures 2018, L.p. | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocus Research • 11-07-2023
By Tiesvg Tiesvg • 01-02-2023
By PRNewswire PRNewswire • 01-04-2023
By Marketwired • 09-21-2023
By GuruFocus Research • 09-16-2023
By Marketwired • 10-12-2023
By sperokesalga sperokesalga • 05-10-2023
By GuruFocus Research • 12-28-2023
By Marketwired • 08-10-2023
By GuruFocus Research GuruFocus Editor • 10-25-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.